Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report)’s stock price fell 3.7% during mid-day trading on Tuesday after Wall Street Zen downgraded the stock from a hold rating to a sell rating. The stock traded as low as $3.09 and last traded at $3.12. 3,103,838 shares changed hands during mid-day trading, a decline of 4% from the average session volume of 3,243,728 shares. The stock had previously closed at $3.24.
Prime Medicine Stock Down 3.7%
The company has a market capitalization of $419.86 million, a price-to-earnings ratio of -2.00 and a beta of 2.38.
About Prime Medicine
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.
Featured Stories
- Five stocks we like better than Prime Medicine
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Amazon Faces Rare Downgrade—Is the Rally at Risk?
- How to Read Stock Charts for Beginners
- CrowdStrike Tests $412 Support as Options Traders Turn Bullish
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Dueling Insider Moves: Heavy Buying Here, Big Selling There
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
